2022-RA-1196-ESGO Secondary cytoreductive surgery in endometrial cancer recurrence: how to triage patients towards surgery, a multicenter study
Virginia Vargiu(Agostino Gemelli University Polyclinic), Francesco Cosentino, Giovanni Scambia(Agostino Gemelli University Polyclinic), Vito Andrea Capozzi(University of Parma), Ettore Distefano(Agostino Gemelli University Polyclinic), Alessandro Gioè(Agostino Gemelli University Polyclinic), Roberto Berretta(University of Parma), Stefano Restaino(University of Udine), Andrea Rosati(Agostino Gemelli University Polyclinic), Francesco Fanfani(Agostino Gemelli University Polyclinic)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta‐analysis
|Ultrasound in Obstetrics and Gynecology|2017|299